Published September 18, 2024 U.S. Pharmacist Weekly News Update | October 2, 2024 l House Ad By Staff U.S. Pharmacist Weekly News October 2, 2024 New Pneumococcal Vaccine Covers Eight Additional Serotypes Just days after the new pneumococcal conjugate vaccine 21 was approved by the FDA this past June, a CDC committee recommended a single dose of it for adults aged 19 years and older. Find out what was behind the decision and what benefits the new vaccine, marketed as Capvaxive, offers compared with older pneumonia vaccines. Antihypertensive Deprescribing Linked to Less Cognitive Decline Deprescribing antihypertensive medication in nursing home residents was associated with less cognitive decline, according to a new study published in the Journal of the American Medical Association. In fact, those diagnosed with dementia especially benefited. Find out how the study team reached those conclusions in their effort to reduce polypharmacy in the older residents. Cholesterol Drug Shows Promise for Preventing Alzheimer’s Disease Inflammation appears to play an early role in Alzheimer’s disease. By screening the proteins involved in that process against FDA-approved drug structures, a study team identified the possibility of a strong affinity for ezetimibe, a common nonstatin medication that inhibits the absorption of cholesterol in the intestines, in their recent study published in Aging Biology. Read more. FDA Approves Nymalize Oral Prefilled-Syringe Solution Azurity Pharmaceuticals recently announced the FDA approval of Nymalize (nimodipine) oral solution in a 30-mg/5-mL prefilled ENFit syringe. Nymalize is indicated for the improvement of neurological outcomes by decreasing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, irrespective of their postictus neurological condition (i.e., Hunt and Hess Grades I-V). Read more. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -